Jul 2, 2026
In this solo episode, Steve Vinson explores the rapidly evolving obesity drug market, highlighting insights from a recent Fierce Biotech power rankings article. He breaks down why Lilly and Novo Nordisk currently dominate, while examining the growing competitive field and what may determine the next wave of winners....
Jul 1, 2026
In this episode, Steve Vinson examines the sustained wave of biopharma manufacturing investment in North America and challenges the idea that tariffs were the primary driver. He explores the deeper forces reshaping the industry, including supply chain resilience, demand for complex biologics, and global...